Clinical Trial Update: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating oral Epigallocatechin-3-gallate (EGCG) in patients with Idiopathic Pulmonary Fibrosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Epigallocatechin-3-gallate (EGCG) (Epigallocatechin-3-gallate)

Snippet

Sponsor: Hal Chapman | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED